JP2018533591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533591A5 JP2018533591A5 JP2018523451A JP2018523451A JP2018533591A5 JP 2018533591 A5 JP2018533591 A5 JP 2018533591A5 JP 2018523451 A JP2018523451 A JP 2018523451A JP 2018523451 A JP2018523451 A JP 2018523451A JP 2018533591 A5 JP2018533591 A5 JP 2018533591A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- siglec15
- modulator
- item
- siglec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121460A JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253437P | 2015-11-10 | 2015-11-10 | |
| US62/253,437 | 2015-11-10 | ||
| PCT/US2016/061086 WO2017083354A1 (en) | 2015-11-10 | 2016-11-09 | Compositions and methods for treating autoimmune diseases and cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121460A Division JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533591A JP2018533591A (ja) | 2018-11-15 |
| JP2018533591A5 true JP2018533591A5 (https=) | 2019-12-05 |
| JP6924495B2 JP6924495B2 (ja) | 2021-08-25 |
Family
ID=58695157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018523451A Active JP6924495B2 (ja) | 2015-11-10 | 2016-11-09 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2021121460A Pending JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2023081549A Pending JP2023096078A (ja) | 2015-11-10 | 2023-05-17 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2025129444A Pending JP2025156500A (ja) | 2015-11-10 | 2025-08-01 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121460A Pending JP2021167353A (ja) | 2015-11-10 | 2021-07-26 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2023081549A Pending JP2023096078A (ja) | 2015-11-10 | 2023-05-17 | 自己免疫疾患およびがんを処置するための組成物および方法 |
| JP2025129444A Pending JP2025156500A (ja) | 2015-11-10 | 2025-08-01 | 自己免疫疾患およびがんを処置するための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180318419A1 (https=) |
| EP (2) | EP4512827A3 (https=) |
| JP (4) | JP6924495B2 (https=) |
| KR (1) | KR102810368B1 (https=) |
| CN (2) | CN116510015A (https=) |
| AU (2) | AU2016354100B2 (https=) |
| BR (1) | BR112018009361A8 (https=) |
| CA (1) | CA3002095A1 (https=) |
| HK (1) | HK1259294A1 (https=) |
| MX (2) | MX2018005830A (https=) |
| RU (1) | RU2761980C2 (https=) |
| TW (2) | TWI847955B (https=) |
| WO (1) | WO2017083354A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| AU2017330346C1 (en) | 2016-09-21 | 2025-03-06 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
| CN113138273B (zh) * | 2020-01-17 | 2024-06-18 | 孟民杰 | 一种应用于肺癌快速筛查及免疫靶向治疗检测的试剂盒及其用途 |
| AU2021240769B2 (en) * | 2020-03-27 | 2023-04-06 | Biosion Inc. | Antibodies binding Siglec15 and uses thereof |
| CN113817057B (zh) * | 2020-06-19 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗siglec15抗体及其应用 |
| CN114525256A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用 |
| EP4032973B1 (en) * | 2021-01-21 | 2023-07-19 | Guizhou Sinorda Biotechnology CO., Ltd. | Modified t cells for adoptive immunotherapy |
| CA3204359A1 (en) * | 2020-12-08 | 2022-06-16 | Guizhou Sinorda Biotechnology Co. Ltd. | Modified t cells for adoptive immunotherapy |
| CN114657132A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15靶向抑制因子的多能干细胞及其衍生物与应用 |
| IL305409A (en) * | 2021-02-23 | 2023-10-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Preparation of SIGLEC-15 binding protein and its use |
| CN114957468A (zh) * | 2021-02-25 | 2022-08-30 | 石药集团巨石生物制药有限公司 | 一种抗Siglec15抗体及其用途 |
| CN114751973B (zh) * | 2021-03-12 | 2024-02-20 | 百奥赛图(北京)医药科技股份有限公司 | Siglec15基因人源化非人动物的构建方法和应用 |
| CN116983412A (zh) * | 2023-08-04 | 2023-11-03 | 南通大学 | Siglec-15-SE超增强子在制备治疗肿瘤的产品中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| ATE275415T1 (de) * | 1995-06-27 | 2004-09-15 | Res Foundation Of Cuny Hunter | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält |
| EP2322185A3 (en) * | 2001-11-21 | 2011-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US20100028321A1 (en) * | 2006-08-28 | 2010-02-04 | Omnio Healer Ab | Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| JPWO2009048072A1 (ja) * | 2007-10-11 | 2011-02-17 | 第一三共株式会社 | 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体 |
| RU2539790C2 (ru) | 2009-04-09 | 2015-01-27 | Дайити Санкио Компани, Лимитед | АНТИТЕЛО ПРОТИВ Siglec-15 |
| JP5998060B2 (ja) * | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| BR112013002940A2 (pt) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos |
| JP2013543382A (ja) * | 2010-10-05 | 2013-12-05 | 第一三共株式会社 | 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体 |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| ES2908046T3 (es) * | 2011-09-09 | 2022-04-27 | Medimmune Ltd | Anticuerpos anti-siglec-15 y usos de los mismos. |
| EP2610263A1 (de) * | 2011-12-30 | 2013-07-03 | Brossmer, Reinhard | Sialinsäure-Dimere |
| WO2015054600A2 (en) * | 2013-10-10 | 2015-04-16 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| PL3129067T3 (pl) * | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
-
2016
- 2016-11-09 HK HK19101657.1A patent/HK1259294A1/zh unknown
- 2016-11-09 JP JP2018523451A patent/JP6924495B2/ja active Active
- 2016-11-09 TW TW105136406A patent/TWI847955B/zh active
- 2016-11-09 WO PCT/US2016/061086 patent/WO2017083354A1/en not_active Ceased
- 2016-11-09 RU RU2018121050A patent/RU2761980C2/ru active
- 2016-11-09 EP EP24202238.2A patent/EP4512827A3/en not_active Withdrawn
- 2016-11-09 CN CN202310352979.8A patent/CN116510015A/zh active Pending
- 2016-11-09 TW TW112112070A patent/TW202330019A/zh unknown
- 2016-11-09 US US15/775,084 patent/US20180318419A1/en not_active Abandoned
- 2016-11-09 CN CN201680065576.3A patent/CN108430498A/zh active Pending
- 2016-11-09 EP EP16864893.9A patent/EP3373962A4/en not_active Withdrawn
- 2016-11-09 MX MX2018005830A patent/MX2018005830A/es unknown
- 2016-11-09 KR KR1020187015768A patent/KR102810368B1/ko active Active
- 2016-11-09 BR BR112018009361A patent/BR112018009361A8/pt not_active Application Discontinuation
- 2016-11-09 CA CA3002095A patent/CA3002095A1/en active Pending
- 2016-11-09 AU AU2016354100A patent/AU2016354100B2/en active Active
-
2018
- 2018-05-09 MX MX2023012451A patent/MX2023012451A/es unknown
-
2021
- 2021-07-26 JP JP2021121460A patent/JP2021167353A/ja active Pending
-
2022
- 2022-02-16 US US17/673,034 patent/US20220168419A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081549A patent/JP2023096078A/ja active Pending
-
2024
- 2024-02-27 AU AU2024201282A patent/AU2024201282A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129444A patent/JP2025156500A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533591A5 (https=) | ||
| Haanen et al. | Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy | |
| Hatakeyama et al. | ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments | |
| Liu et al. | Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy | |
| Miyamoto et al. | Molecular pathways: cachexia signaling—a targeted approach to cancer treatment | |
| RU2018121050A (ru) | Композиции и способы лечения аутоиммунных заболеваний и рака | |
| Doebele et al. | Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer | |
| Fujita et al. | C‐reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| Henriques et al. | Toll-like receptor-4 disruption suppresses adipose tissue remodeling and increases survival in cancer cachexia syndrome | |
| Wu et al. | Molecular basis of therapeutic approaches to gastric cancer | |
| MA41038B1 (fr) | Composés d'aminopyridyloxypyrazole | |
| Herrera-Rios et al. | Macrophages/microglia represent the major source of indolamine 2, 3-dioxygenase expression in melanoma metastases of the brain | |
| PH12016501549A1 (en) | Tergeted tgf� inhibition | |
| Farhat et al. | Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? | |
| PH12018502046B1 (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| PH12022550122A1 (en) | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer | |
| Qu et al. | Loss of CD 155 expression predicts poor prognosis in hepatocellular carcinoma | |
| Keddie et al. | Plasma cell depletion with bortezomib in the treatment of refractory N‐methyl‐d‐aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment | |
| Wang et al. | Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer | |
| WO2020115491A3 (en) | Immune checkpoint inhibitor in combination with sonodynamic therapy | |
| MX385589B (es) | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. | |
| Zhu et al. | FBI-1 enhances ETS-1 signaling activity and promotes proliferation of human colorectal carcinoma cells | |
| JOP20220057A1 (ar) | علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii | |
| Nelkin | Recent advances in the biology and therapy of medullary thyroid carcinoma |